Molecules (Apr 2012)
Synthesis and Cytotoxic Activity of Some Novel <em>N</em>-Pyridinyl-2-(6-phenylimidazo[2,1-<em>b</em>]thiazol-3-yl)acetamide Derivatives
Abstract
A series of novel compounds bearing imidazo[2,1-<em>b</em>]thiazole scaffolds were designed and synthesized based on the optimization of the virtual screening hit compound <em>N</em>-(6-morpholinopyridin-3-yl)-2-(6-phenylimidazo[2,1-b]thiazol-3-yl)acetamide (<strong>5a</strong>), and tested for their cytotoxicity against human cancer cell lines, including HepG2 and MDA-MB-231. The results indicated that the compound 2-(6-(4-chlorophenyl)imidazo[2,1-b]thiazol-3-yl)-N-(6-(4-(4-methoxybenzyl)piperazin-1-yl)pyridin-3-yl)acetamide (<strong>5l</strong>), with slightly higher inhibition on VEGFR2 than <strong>5a</strong> (5.72% and 3.76% inhibitory rate at 20 μM, respectively), was a potential inhibitor against MDA-MB-231 (IC<sub>50</sub> = 1.4 μM) compared with sorafenib (IC<sub>50</sub> = 5.2 μM), and showed more selectivity against MDA-MB-231 than HepG2 cell line (IC<sub>50</sub> = 22.6 μM).
